Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates

Nucleic Acids Research

Volumn 45, Issue 19, 2017, Pages 10969-10977

  Nair, Jayaprakash K ^a   Attarwala, Husain ^a   Sehgal, Alfica ^a   Wang, Qianfan ^a   Aluri, Krishna ^a   Zhang, Xuemei ^a   Gao, Minggeng ^a   Liu, Ju ^a   Indrakanti, Ramesh ^a   Schofield, Sally ^a   Kretschmer, Philip ^a   Brown, Christopher R ^a   Gupta, Swati ^a   Willoughby, Jennifer L S ^a   Boshar, Julie A ^a   Jadhav, Vasant ^a   Charisse, Klaus ^a   Zimmermann, Tracy ^a   Fitzgerald, Kevin ^a   Manoharan, Muthiah ^a   Rajeev, Kallanthottathil G ^a   Akinc, Akin ^a   Hutabarat, Renta ^a   Maier, Martin A ^a   more..

^a ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXONUCLEASE; N ACETYLGALACTOSAMINE; OLIGONUCLEOTIDE; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; LIVER CELL; MALE; METABOLIC STABILITY; MOLECULAR PROBE; MOUSE; NONHUMAN; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA SYNTHESIS; ANIMAL; AREA UNDER THE CURVE; C57BL MOUSE; CYTOLOGY; DRUG DELIVERY SYSTEM; HUMAN; KIDNEY; LIVER; METABOLIC CLEARANCE RATE; METABOLISM; PROCEDURES;

ACETYLGALACTOSAMINE; ANIMALS; AREA UNDER CURVE; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY; LIVER; MALE; METABOLIC CLEARANCE RATE; MICE, INBRED C57BL; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 85037980916     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkx818     Document Type: Article

References (31)

1. Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B.R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J.D., Taubel, J., Brooks, A. et al. (2017) A highly durable RNAi therapeutic inhibitor of PCSK9. N. Engl. J. Med., 376, 41-51.
2. Zimmermann, T.S., Karsten, V., Chan, A., Chiesa, J., Boyce, M., Bettencourt, B.R., Hutabarat, R., Nochur, S., Vaishnaw, A. and Gollob, J. (2017) Clinical proof of concept for a novel hepatocyte-Targeting GalNAc-siRNA conjugate. Mol. Ther., 25, 71-78.
3. Wittrup, A. and Lieberman, J. (2015) Knocking down disease: A progress report on siRNA therapeutics. Nat. Rev. Genet., 16, 543-552.
4. Nair, J.K., Willoughby, J.L., Chan, A., Charisse, K., Alam, M.R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel'in, A.V., Milstein, S. et al. (2014) Multivalent N-Acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc., 136, 16958-16961.
5. Rensen, P.C., Sliedregt, L.A., Ferns, M., Kieviet, E., van Rossenberg, S.M., van Leeuwen, S.H., van Berkel, T.J. and Biessen, E.A. (2001) Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J. Biol. Chem., 276, 37577-37584.
6. Rensen, P.C., van Leeuwen, S.H., Sliedregt, L.A., van Berkel, T.J. and Biessen, E.A. (2004) Design and synthesis of novel N-Acetylgalactosamine-Terminated glycolipids for targeting of lipoproteins to the hepatic asialoglycoprotein receptor. J. Med. Chem., 47, 5798-5808.
7. Biessen, E.A., Noorman, F., van Teijlingen, M.E., Kuiper, J., Barrett-Bergshoeff, M., Bijsterbosch, M.K., Rijken, D.C. and van Berkel, T.J. (1996) Lysine-based cluster mannosides that inhibit ligand binding to the human mannose receptor at nanomolar concentration. J. Biol. Chem., 271, 28024-28030.
8. Biessen, E.A., Vietsch, H. and van Berkel, T.J. (1996) Induction of hepatic uptake of lipoprotein(a) by cholesterol-derivatized cluster galactosides. Arterioscler. Thromb. Vasc. Biol., 16, 1552-1558.
9. Huang, X., Leroux, J.C. and Castagner, B. (2017) Well-defined multivalent ligands for hepatocytes targeting via asialoglycoprotein receptor. Bioconj. Chem., 28, 283-295.
10. Rajeev, K.G., Nair, J.K., Jayaraman, M., Charisse, K., Taneja, N., O'Shea, J., Willoughby, J.L., Yucius, K., Nguyen, T., Shulga-Morskaya, S. et al. (2015) Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-Acetylgalactosamine elicits robust gene silencing in vivo. Chem Bio Chem., 16, 903-908.
11. Matsuda, S., Keiser, K., Nair, J.K., Charisse, K., Manoharan, R.M., Kretschmer, P., Peng, C.G., A, V.K.i., Kandasamy, P., Willoughby, J.L. et al. (2015) siRNA conjugates carrying sequentially assembled trivalent N-Acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem. Biol., 10, 1181-1187.
12. Migawa, M.T., Prakash, T.P., Vasquez, G., Wan, W.B., Yu, J., Kinberger, G.A., Ostergaard, M.E., Swayze, E.E. and Seth, P.P. (2016) A convenient synthesis of 5-Triantennary N-Acetyl-galactosamine clusters based on nitromethanetrispropionic acid. Bioorg. Med. Chem. Lett., 26, 2194-2197.
13. Prakash, T.P., Graham, M.J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H.F. et al. (2014) Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-Acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res., 42, 8796-8807.
14. Prakash, T.P., Yu, J., Migawa, M.T., Kinberger, G.A., Wan, W.B., Ostergaard, M.E., Carty, R.L., Vasquez, G., Low, A., Chappell, A. et al. (2016) Comprehensive structure-Activity relationship of triantennary N-Acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes. J. Med. Chem., 59, 2718-2733.
15. Yu, R.Z., Graham, M.J., Post, N., Riney, S., Zanardi, T., Hall, S., Burkey, J., Shemesh, C.S., Prakash, T.P., Seth, P.P. et al. (2016) Disposition and pharmacology of a GalNAc3-conjugated ASO targeting human lipoprotein (a) in mice. Mol. Ther.-Nucleic Acids, 5, e317.
16. Yu, R.Z., Gunawan, R., Post, N., Zanardi, T., Hall, S., Burkey, J., Kim, T.W., Graham, M.J., Prakash, T.P., Seth, P.P. et al. (2016) Disposition and pharmacokinetics of a GalNAc3-conjugated antisense oligonucleotide targeting human lipoprotein (a) in monkeys. Nucleic Acid Ther., 26, 372-380.
17. Mukherjee, D., Fritz, D.T., Kilpatrick, W.J., Gao, M. and Wilusz, J. (2004) Analysis of RNA exonucleolytic activities in cellular extracts. Methods Mol. Biol., 257, 193-212.
18. Cummins, L.L., Owens, S.R., Risen, L.M., Lesnik, E.A., Freier, S.M., McGee, D., Guinosso, C.J. and Cook, P.D. (1995) Characterization of fully 2-modified oligoribonucleotide hetero-And homoduplex hybridization and nuclease sensitivity. Nucleic Acids Res., 23, 2019-2024.
19. Layzer, J.M., McCaffrey, A.P., Tanner, A.K., Huang, Z., Kay, M.A. and Sullenger, B.A. (2004) In vivo activity of nuclease-resistant siRNAs. RNA, 10, 766-771.
20. Takahashi, M., Minakawa, N. and Matsuda, A. (2009) Synthesis and characterization of 2-modified-4-ThioRNA: A comprehensive comparison of nuclease stability. Nucleic Acids Res., 37, 1353-1362.
21. Allerson, C.R., Sioufi, N., Jarres, R., Prakash, T.P., Naik, N., Berdeja, A., Wanders, L., Griffey, R.H., Swayze, E.E. and Bhat, B. (2005) Fully 2-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem., 48, 901-904.
22. Prakash, T.P., Kinberger, G.A., Murray, H.M., Chappell, A., Riney, S., Graham, M.J., Lima, W.F., Swayze, E.E. and Seth, P.P. (2016) Synergistic effect of phosphorothioate, 5-vinylphosphonate and GalNAc modifications for enhancing activity of synthetic siRNA. Bioorg. Med. Chem. Lett., 26, 2817-2820.
23. Chan, A., Liebow, A., Yasuda, M., Gan, L., Racie, T., Maier, M., Kuchimanchi, S., Foster, D., Milstein, S., Charisse, K. et al. (2015) Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification. Mol. Ther.-Nucleic Acids, 4, e263.
24. Liebow, A., Li, X., Racie, T., Hettinger, J., Bettencourt, B.R., Najafian, N., Haslett, P., Fitzgerald, K., Holmes, R.P., Erbe, D. et al. (2017) An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria. J. Am. Soc. Nephrol., 28, 494-503.
25. Sehgal, A., Barros, S., Ivanciu, L., Cooley, B., Qin, J., Racie, T., Hettinger, J., Carioto, M., Jiang, Y., Brodsky, J. et al. (2015) An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat. Med., 21, 492-497.
26. Beaucage, S.L. (2008) Solid-phase synthesis of siRNA oligonucleotides. Curr. Opin. Drug Discov. Dev., 11, 203-216.
27. Mueller, S., Wolf, J. and Ivanov, S.A. (2004) Current strategies for the synthesis of RNA. Curr. Org. Synth., 1, 293-307.
28. Guzaev, A.P. (2011) Reactivity of 3H-1, 2, 4-dithiazole-3-Thiones and 3H-1, 2-dithiole-3-Thiones as sulfurizing agents for oligonucleotide synthesis. Tetrahedron Lett., 52, 434-437.
29. Parmar, R., Willoughby, J.L., Liu, J., Foster, D.J., Brigham, B., Theile, C.S., Charisse, K., Akinc, A., Guidry, E., Pei, Y. et al. (2016) 5'-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates. Chembiochem., 17, 985-989.
30. Elkayam, E., Parmar, R., Brown, C.R., Willoughby, J.L., Theile, C.S., Manoharan, M. and Joshua-Tor, L. (2017) siRNA carrying an (E)-vinylphosphonate moiety at the 5 end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2. Nucleic Acids Res., 45, 3528-3536.
31. Pei, Y., Hancock, P.J., Zhang, H., Bartz, R., Cherrin, C., Innocent, N., Pomerantz, C.J., Seitzer, J., Koser, M.L., Abrams, M.T. et al. (2010) Quantitative evaluation of siRNA delivery in vivo. RNA, 16, 2553-2563.